CRPS Treatment in Lower Merion Township, PA

CRPS Is One of the Most Painful Conditions Known to Medicine. It Deserves One of the Most Targeted Treatments Available.

The McGill Pain Index ranks complex regional pain syndrome among the most severe pain conditions ever documented, scoring higher than childbirth, amputation, and most forms of cancer pain. People who live with CRPS are not exaggerating. They are describing a neurological event in which the nervous system has become catastrophically dysregulated, producing and amplifying pain on a continuous loop far beyond any injury the body originally sustained.

Standard treatments for CRPS, nerve blocks, spinal cord stimulators, physical therapy, anticonvulsants, and opioids, provide meaningful relief for some patients and inadequate relief for far too many others. When those approaches stop working or never work in the first place, IV ketamine represents the best-evidenced non-surgical option currently available for refractory CRPS. It is the one intervention with two double-blind, placebo-controlled randomized trials specifically in CRPS patients, both demonstrating superior analgesia lasting up to 12 weeks from a single multiday infusion course.

At Ketamine Wellness Infusions PA, located minutes from Lower Merion Township in Bala Cynwyd, we offer IV ketamine infusions specifically for CRPS patients who have not achieved adequate relief through conventional treatment. Our founder Jill Gabay is a senior CRNA with more than 30 years of anesthesia experience and a member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners. She is personally present for every infusion.

If you or someone you love is living with CRPS, schedule a consultation. The evidence for what we offer is specific, strong, and directly relevant to your diagnosis.

What CRPS Is and Why It Is So Difficult to Treat

Complex regional pain syndrome is a chronic neurological condition most commonly affecting one limb, typically developing after an injury, surgery, or other trauma to that limb. What makes CRPS categorically different from ordinary post-injury pain is the disproportionality of the response: the pain is dramatically worse than what the original injury would predict, persists and often intensifies long after healing should be complete, and develops a constellation of additional symptoms that go far beyond pain itself.

These additional symptoms include allodynia, meaning pain triggered by light touch or mild stimuli, hyperalgesia, an amplified pain response to stimuli that should produce only minor discomfort, changes in skin color and temperature in the affected limb, swelling, abnormal sweating, and in progressive cases, motor dysfunction and muscle wasting. CRPS is classified into two types. CRPS Type I, previously called reflex sympathetic dystrophy, occurs without identifiable nerve damage and accounts for the majority of cases. CRPS Type II, previously called causalgia, involves identifiable nerve injury. Both types share the same symptom profile and the same treatment challenges.

The underlying neurobiology involves dysfunction in both the peripheral and central nervous systems. At the central level, NMDA receptor-mediated sensitization at dorsal horn synapses drives and maintains the amplified pain response. Long-term potentiation, the process by which repeated neural stimulation strengthens synaptic transmission, is believed to be a primary mechanism underlying the allodynia, hyperalgesia, and central sensitization that characterize CRPS. Inflammatory processes, autonomic dysregulation, and altered neuroplasticity compound the central sensitization mechanism, making CRPS a multi-system neurological disorder rather than a simple pain condition.

This is why standard analgesic approaches tend to provide only partial or temporary relief. They address pain signal transmission without dismantling the neurological machinery generating the abnormal pain state.

What the Research Says About Ketamine for CRPS

Of all the chronic pain conditions for which ketamine has been studied, CRPS has the most direct and specifically designed clinical trial evidence. This is not incidental. Researchers identified CRPS as a priority target for ketamine precisely because the NMDA receptor-driven central sensitization mechanism that ketamine blocks is so central to how CRPS operates.

Two randomized double-blind placebo-controlled trials have specifically tested IV ketamine in CRPS patients.

The Schwartzman trial, published in Pain in 2009, enrolled patients with CRPS who had been in pain for more than six months and who had failed conservative treatment including nerve blocks, opioids, and NSAIDs. Patients received a 10-day series of outpatient subanesthetic ketamine infusions, with doses reaching a maximum of 0.35 mg/kg per hour for four hours daily. The results demonstrated superior analgesia for up to 12 weeks compared to placebo infusions.

The Sigtermans trial, also published in Pain in 2009, enrolled 60 CRPS Type I patients in a double-blind randomized placebo-controlled parallel-group trial. Patients received a four-day continuous subanesthetic ketamine infusion titrated to individual response. Significant pain relief was achieved for up to six weeks compared to placebo, with a notable finding that disease duration did not predict treatment response, meaning patients with both recent-onset and long-standing CRPS benefited.

Both studies demonstrated that subanesthetic multiday infusion regimens can yield 11 to 12 weeks of meaningful pain relief. A retrospective case series examining subanesthetic inpatient ketamine infusions for refractory CRPS found complete pain relief in 76% of patients and partial relief in 18%, with only 6% experiencing no benefit.

Research published in PMC on ketamine's analgesic mechanism in CRPS describes how NMDA receptor antagonism is thought to reverse long-term potentiation, directly addressing the central sensitization and allodynia that are hallmarks of the condition. The 2018 consensus guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists identify CRPS specifically as a condition for which IV ketamine has documented clinical utility and provide evidence-based dosing recommendations.

A systematic review of ketamine for CRPS published in PMC found that pain relief from a single infusion course could last three to six months, with duration extending to one to three years with a second infusion course in responsive patients.

How IV Ketamine Addresses CRPS at the Neurological Level

CRPS is a disease of the nervous system. Treating it at the nervous system level, rather than purely at the peripheral symptom level, is the principle behind ketamine's clinical rationale.

By blocking NMDA receptors, ketamine interrupts the long-term potentiation mechanism driving central sensitization in the dorsal horn. It reduces wind-up, the progressive amplification of pain signals with repeated stimulation that is a direct expression of CRPS-associated sensitization. It restores descending inhibition, the brain's own capacity to suppress pain signals from below, which is characteristically impaired in CRPS. And it exerts neuroimmune modulation effects that address the inflammatory component of CRPS, particularly relevant in the acute and subacute stages of the condition.

Research from PMC analyzing ketamine's mechanism in CRPS notes that NMDA receptors are necessary for long-term potentiation, and that ketamine's antagonism of these receptors is thought to reverse the hyperalgesia, allodynia, and central sensitization seen in CRPS. The analgesic mechanism may also involve ketamine's interaction with opioid, GABA, dopamine, and calcium channel receptors, producing a multi-pathway effect on the abnormal neural signaling that sustains CRPS.

The practical result is that for patients who respond, IV ketamine does not simply suppress CRPS symptoms during the infusion. It appears to produce a neurological reset that outlasts the treatment itself, with relief persisting for weeks to months after the infusion course is complete.

What Treatment Looks Like at Our Clinic

Your consultation begins with Jill Gabay reviewing your CRPS diagnosis, the history and location of your symptoms, your current treatment regimen, prior interventions including nerve blocks and spinal cord stimulator trials, and your overall health picture. CRPS frequently co-occurs with depression, anxiety, and sleep disorders, and the full clinical picture shapes the approach.

The standard initial course is six IV ketamine infusions completed over approximately two to three weeks. Each session lasts 40 to 60 minutes in a calm, dedicated room with blankets, an eye mask, and essential oil diffusers. Jill or a member of our care team is present throughout every infusion with continuous vital sign monitoring. For CRPS patients, whose nervous systems are already in a state of hyperreactivity, the calm and controlled environment of the infusion room is not a cosmetic detail. It matters clinically.

After your series, Jill conducts personal follow-up check-ins to assess your response and plan next steps. Patients who respond well to an initial course may benefit from periodic maintenance infusions. The research on CRPS specifically supports the value of subsequent infusion courses in extending the duration of relief for initial responders. Your ongoing plan is built around your actual response.

Why Lower Merion Township CRPS Patients Choose Our Clinic

Our clinic at 146 Montgomery Ave, Suite 202 in Bala Cynwyd sits inside Lower Merion Township, minutes from Ardmore, Wynnewood, Narberth, Penn Valley, Bryn Mawr, and the broader Main Line area. For CRPS patients managing severe pain, the proximity to treatment without a Philadelphia commute matters.

What makes this clinic specifically suited to CRPS care is Jill Gabay's depth of expertise in ketamine pharmacology and infusion management at subanesthetic doses. CRPS is the chronic pain condition most thoroughly studied with IV ketamine, and the protocols used matter significantly. Her 30 years of anesthesia experience, combined with her membership in the American Society of Ketamine Physicians, Psychotherapists and Practitioners, means she brings clinical precision to dosing decisions that a less specialized provider cannot.

Her physician supervisor Dr. Rubin brings more than 20 years of clinical experience as a board-certified oncologist and Clinical Associate Professor at Drexel University College of Medicine. We hold a 5.0 Google rating. Patients who have come to us after years of inadequate pain control describe the care as personal, attentive, and genuinely different from the transactional clinical experiences that often characterize chronic pain management.

Frequently Asked Questions About CRPS Treatment in Lower Merion Township